News brief­ing: Check­point reads out new in­ter­im mC­SCC da­ta; Taysha eyes $125M for its flash IPO

Check­point Ther­a­peu­tics has read out up­dat­ed in­ter­im Phase I da­ta for its an­ti-PD-L1 an­ti­body cosi­be­limab in a reg­is­tra­tion-en­abling co­hort of metasta­t­ic cu­ta­neous squa­mous cell car­ci­no­ma pa­tients. And the New York-based biotech plans to com­pete with ri­vals by “sub­stan­tial­ly low­er­ing” costs.

The in­ter­im re­sults, which were pre­sent­ed at ES­MO, showed Check­point’s drug achieved a 51.4% ob­jec­tive re­sponse rate (ORR) and 13.5% com­plete re­sponse (CR) rate — near­ly dou­bling the com­plete re­sponse rate ob­served dur­ing its last analy­sis, ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER